Clinical Trials
13 trialsNCT01222286 2026-05-14
KIRMONO
Innate Pharma
Phase 2 Completed
NCT04731844 2026-05-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Completed
NCT02316106 2026-04-23
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01237054 2026-02-06
Imaging in MGUS, SMM and MM
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02903381 2023-06-13
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02279394 2023-06-09
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01302886 2020-12-17
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Novartis
Phase 2 Completed
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed
NCT01884688 2017-04-17
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT00099047 2016-12-30
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Phase 2 Completed